Recent worldwide emergence of CA-MRSA has prompted the development of several new antibiotics (see Table 2). In the past, as vancomycin became less effective against MRSA, clinicians turned to ...
Dalba vancin and oritavancin have shown bactericidal activity against MRSA, VRSA, VRE, and DRSP and are undergoing the final stages of clinical trials (Bradley, 2005; Hoffman-Roberts et al., ...
AZoLifeSciences on MSN12d
Mechanisms of Antibiotic Resistance: A Molecular PerspectiveThe rise of antibiotic resistance demands urgent research into its molecular mechanisms to inform the development of ...
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. Basilea secured the license ...
Background: Methicillin resistant Staphylococcus aureus (MRSA) is a Gram-positive bacterium that can cause local or systemic infectious diseases, and treatment for MRSA has become a major global ...
These bacteria are called methicillin-resistant Staphylococcus aureus (MRSA). To determine which antibiotics are effective against the staph, healthcare providers can perform an antibiotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback